menu
    • menu

    Company profile for Braeburn

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid use disorder. We are committed to advancing next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare professionals, payers and society. Braeburn has one mission: to fight the opioid epid...
    Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid use disorder. We are committed to advancing next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare professionals, payers and society. Braeburn has one mission: to fight the opioid epidemic. The work we are doing can make a difference in the lives of patients who often shoulder the burden of treatment themselves.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BraeburnUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    450 Plymouth Rd, Suite 400 Plymouth Meeting, PA 19462
    Telephone
    Telephone
    +1 610-467-8680
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://braeburnrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/braeburn/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/braeburnrx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Braeburn Publishes Post Hoc Analysis of Phase 3 Study Data on BRIXADI
    Braeburn Publishes Post Hoc Analysis of Phase 3 Study Data on BRIXADI

    25 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/braeburn-announces-publication-of-a-post-hoc-analysis-of-data-from-patients-using-fentanyl-treated-with-brixadi-in-a-phase-3-efficacy-and-safety-study-302181924.html

    PR NEWSWIRE
    25 Jun 2024
    Share Share
    FDA Accepts Braeburn's NDA Resubmission for BRIXADI Subcutaneous Injection
    FDA Accepts Braeburn's NDA Resubmission for BRIXADI Subcutaneous Injection

    08 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/fda-accepts-braeburns-new-drug-application-resubmission-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301698779.html

    PRNEWSWIRE
    08 Dec 2022
    Share Share
    FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADi
    FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADi

    26 Jun 2021

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-accepts-braeburns-new-drug-application-resubmission-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301320543.html

    PR NEWSWIRE
    26 Jun 2021
    Share Share
    Braeburn Resubmits New Drug Application for BRIXADI
    Braeburn Resubmits New Drug Application for BRIXADI

    15 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/braeburn-resubmits-new-drug-application-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301313130.html

    PRNEWSWIRE
    15 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search